New York State Teachers Retirement System Sells 600 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

New York State Teachers Retirement System decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,289 shares of the medical instruments supplier’s stock after selling 600 shares during the quarter. New York State Teachers Retirement System’s holdings in LeMaitre Vascular were worth $404,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in LMAT. BlackRock Inc. boosted its stake in LeMaitre Vascular by 7.9% during the 4th quarter. BlackRock Inc. now owns 2,979,061 shares of the medical instruments supplier’s stock valued at $120,651,000 after purchasing an additional 217,337 shares during the period. Copeland Capital Management LLC boosted its stake in LeMaitre Vascular by 30.7% during the 4th quarter. Copeland Capital Management LLC now owns 913,569 shares of the medical instruments supplier’s stock valued at $36,999,000 after purchasing an additional 214,590 shares during the period. Scout Investments Inc. bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth approximately $9,063,000. Rice Hall James & Associates LLC lifted its position in shares of LeMaitre Vascular by 421.9% in the 4th quarter. Rice Hall James & Associates LLC now owns 208,051 shares of the medical instruments supplier’s stock worth $8,426,000 after acquiring an additional 168,188 shares during the period. Finally, Morgan Stanley lifted its position in shares of LeMaitre Vascular by 175.9% in the 4th quarter. Morgan Stanley now owns 187,884 shares of the medical instruments supplier’s stock worth $7,608,000 after acquiring an additional 119,797 shares during the period. Hedge funds and other institutional investors own 84.17% of the company’s stock.

A number of analysts have commented on the company. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Wednesday, May 5th. KeyCorp assumed coverage on LeMaitre Vascular in a report on Friday, February 12th. They issued a “sector weight” rating for the company. Barrington Research increased their target price on LeMaitre Vascular from $49.00 to $59.00 and gave the stock an “outperform” rating in a report on Friday, April 30th. Lake Street Capital increased their target price on LeMaitre Vascular from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, April 30th. Finally, Roth Capital increased their target price on LeMaitre Vascular from $53.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $49.67.

In other news, CEO George W. Lemaitre sold 7,200 shares of the firm’s stock in a transaction on Monday, May 10th. The stock was sold at an average price of $49.87, for a total value of $359,064.00. Following the transaction, the chief executive officer now directly owns 2,592,425 shares in the company, valued at approximately $129,284,234.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 42,869 shares of the firm’s stock in a transaction on Monday, March 1st. The stock was sold at an average price of $51.41, for a total value of $2,203,895.29. Following the completion of the transaction, the chief executive officer now owns 2,796,567 shares in the company, valued at $143,771,509.47. The disclosure for this sale can be found here. Insiders sold a total of 257,954 shares of company stock valued at $13,136,847 over the last three months. Insiders own 16.50% of the company’s stock.

NASDAQ LMAT opened at $47.95 on Thursday. The stock has a fifty day moving average of $50.30 and a 200-day moving average of $44.25. The stock has a market capitalization of $987.34 million, a P/E ratio of 51.56, a price-to-earnings-growth ratio of 3.52 and a beta of 1.43. LeMaitre Vascular, Inc. has a 52 week low of $23.40 and a 52 week high of $54.96. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.27 and a current ratio of 2.30.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, April 29th. The medical instruments supplier reported $0.28 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.28. LeMaitre Vascular had a return on equity of 12.32% and a net margin of 15.41%. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 3rd. Stockholders of record on Wednesday, May 19th will be paid a $0.11 dividend. The ex-dividend date of this dividend is Tuesday, May 18th. This represents a $0.44 annualized dividend and a dividend yield of 0.92%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 50.00%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Featured Article: Understanding the different types of bonds

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.